Back to Journals » Lung Cancer: Targets and Therapy
Lung Cancer: Targets and Therapy
- View all (212)
- Volume 17, 2026 (4)
- Volume 16, 2025 (17)
- Volume 15, 2024 (19)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Journal Articles:
- 212 records -
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer
Liu SYM, Xie Z, Yan L, Jie GL, Deng JY, Zhang Q, Huang Z, Wang J, Zhang Z, Shao Y, Meng H, Zhang Y, Zhang XC, Chen HJ, Zhong WZ, Zhou Q, Wu YL
Lung Cancer: Targets and Therapy 2026, 17:596080
Published Date: 8 May 2026
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients
Lumjiaktase P, Kemawichanurat N, Santiwiwas K, Kuttiyod T, Oranratnachai S, Trachu N, Monnamo N, Khiewngam K, Simmalee K, Reungwetwattana T
Lung Cancer: Targets and Therapy 2026, 17:578622
Published Date: 16 March 2026
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
Zhou J, Wang Y, Peng J, Tang KJ, Wu J, Chen Y, Xue Z, Wu YL
Lung Cancer: Targets and Therapy 2026, 17:555262
Published Date: 18 February 2026
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
Schraps N, Reck M, Hantzsch-Kuhn B, Olchers T, Ellebrecht DB, Möller K, Fraune C, Lennartz M, Lutz F, Kluth M, Makrypidi-Fraune G, Simon R, Sauter G, Steurer S, Von Weihe S
Lung Cancer: Targets and Therapy 2026, 17:530791
Published Date: 6 January 2026
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
Lee ATM, Park CJ, Arter ZL, Nagasaka M, Ou SHI
Lung Cancer: Targets and Therapy 2025, 16:199-203
Published Date: 25 December 2025
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
Elayeh E, Aleidi SM, Aboud O, Semreen MH, Bustanji YK, Dahabiyeh LA
Lung Cancer: Targets and Therapy 2025, 16:167-198
Published Date: 16 December 2025
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker
Schneider Galvão G, Fávero Prietto dos Santos J, Hsu YHR, Rogalla P
Lung Cancer: Targets and Therapy 2025, 16:161-166
Published Date: 10 December 2025
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
Hu Y, Ou SHI
Lung Cancer: Targets and Therapy 2025, 16:147-159
Published Date: 31 October 2025
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
Ou SHI, Park CJ, Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2025, 16:139-145
Published Date: 22 October 2025
Tumor Heterogeneity and Plasticity in Small Cell Lung Cancer
Duronio GN, Sage J
Lung Cancer: Targets and Therapy 2025, 16:125-138
Published Date: 10 October 2025
Emerging Targets in Non-Small Cell Lung Cancer
Wang J, Biglow L, Baumgart M
Lung Cancer: Targets and Therapy 2025, 16:115-124
Published Date: 6 September 2025
Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)
Descourt R, Guisier F, Pérol M, Cadranel J, Doubre H, Duruisseaux M, Culine S, Mennecier B, Bylicki O, Chouaid C, Greillier L
Lung Cancer: Targets and Therapy 2025, 16:107-114
Published Date: 12 August 2025
Epidermal Growth Factor Receptor Kinase Domain Duplication in Lung Adenocarcinoma with Sensitive Response to Afatinib: A Case Report and Literature Review
Chen S, Zhang L, Wang J, Lu J, Chen Y, Ling M
Lung Cancer: Targets and Therapy 2025, 16:97-105
Published Date: 12 August 2025
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients
Canale M, Virga A, Angeli D, Fonzi E, Gnetti L, Dubini A, Tedaldi G, Urbini M, Bocchialini G, Petracci E, Verlicchi A, Cravero P, Citarella F, Bennati C, Andrikou K, Delmonte A, Crinò L, Carbognani P, Ulivi P, Ampollini L
Lung Cancer: Targets and Therapy 2025, 16:85-96
Published Date: 28 June 2025
Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma
Du H, Song X, Wu F
Lung Cancer: Targets and Therapy 2025, 16:73-83
Published Date: 9 June 2025
Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cells
Polonio-Alcalá E, Ausellé-Bosch S, Riesco-Llach G, Novales P, Feliu L, Planas M, Ciurana J, Puig T
Lung Cancer: Targets and Therapy 2025, 16:57-72
Published Date: 27 May 2025
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Luo FX, Arter Z, Ou SI, Nagasaka M
Lung Cancer: Targets and Therapy 2025, 16:51-55
Published Date: 25 April 2025
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study
Dao TV, Dinh VL, Doan TV, Phuong TL
Lung Cancer: Targets and Therapy 2025, 16:39-49
Published Date: 21 April 2025
Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer
Chen CY, Ko HW, Hu PW, Chang CY, Chen CY, Chang SC, Chiu YC, Wei YF
Lung Cancer: Targets and Therapy 2025, 16:25-37
Published Date: 12 April 2025
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival
Canale M, Urbini M, Petracci E, Angeli D, Tedaldi G, Priano I, Cravero P, Flospergher M, Andrikou K, Bennati C, Tassinari D, Dubini A, Rossi G, Panzacchi R, Valli M, Bronte G, Crinò L, Delmonte A, Ulivi P
Lung Cancer: Targets and Therapy 2025, 16:11-23
Published Date: 20 February 2025
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC
Arter ZL, Shieh K, Nagasaka M, Ou SHI
Lung Cancer: Targets and Therapy 2025, 16:1-9
Published Date: 19 February 2025
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
Lee AT, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:169-176
Published Date: 17 December 2024
Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
Luo FX, Arter ZL
Lung Cancer: Targets and Therapy 2024, 15:161-167
Published Date: 30 October 2024
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
Shim JS, Kim Y, Yuh T, Lee JB, Kim HR, Hong MH, Cho BC, Lim SM
Lung Cancer: Targets and Therapy 2024, 15:149-159
Published Date: 30 October 2024
NRG1 Fusions in NSCLC: Being eNRGy Conscious
Gupta B, Gosa Barrett L, Liu SV
Lung Cancer: Targets and Therapy 2024, 15:143-148
Published Date: 3 October 2024
Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the Literature
Liu Q, Zhang J, Wei M, Zhou X, Sun H, Dong Y, Zhang D
Lung Cancer: Targets and Therapy 2024, 15:135-142
Published Date: 29 August 2024
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:129-133
Published Date: 28 August 2024
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation
Zhu J, Chen J, Liu W, Zhang J, Gu Y
Lung Cancer: Targets and Therapy 2024, 15:123-128
Published Date: 27 August 2024
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:115-121
Published Date: 9 July 2024
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DW, Santos ES, Shum E, Lau SC, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, Tanizaki J, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, Soo RA
Lung Cancer: Targets and Therapy 2024, 15:87-114
Published Date: 22 June 2024
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?
Lee JB, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:81-85
Published Date: 25 May 2024
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:75-80
Published Date: 23 May 2024
“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)
Luo FX, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:69-73
Published Date: 18 May 2024
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
González-Cao M, Cai X, Bracht JWP, Han X, Yang Y, Pedraz-Valdunciel C, Morán T, García-Corbacho J, Aguilar A, Bernabé R, De Marchi P, Sussuchi da Silva L, Leal LF, Reis RM, Codony-Servat J, Jantus-Lewintre E, Molina-Vila MA, Cao P, Rosell R
Lung Cancer: Targets and Therapy 2024, 15:55-67
Published Date: 9 May 2024
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
Kaakour D, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:49-54
Published Date: 23 April 2024
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:41-47
Published Date: 12 April 2024
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
Dou XJ, Ma RY, Ren DW, Liu Q, Yan P
Lung Cancer: Targets and Therapy 2024, 15:29-40
Published Date: 25 March 2024
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:19-27
Published Date: 27 February 2024
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu’s Approach
Wang B, Wang J, Sun T, Ding Y, Li S, Lu H
Lung Cancer: Targets and Therapy 2024, 15:9-17
Published Date: 2 February 2024
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:1-8
Published Date: 25 January 2024
Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Nagasaka M, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:101-109
Published Date: 12 December 2023
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer
Shi J, Li J, Wang H, Li X, Wang Q, Zhao C, Cheng L, Han R, Chen P, Guo H, Tang Z, Zhou C, Zhang Z, Wu F
Lung Cancer: Targets and Therapy 2023, 14:85-99
Published Date: 21 November 2023
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
Wang L, Quan F, Guo Z, Lu Z, Yang D, Shi M
Lung Cancer: Targets and Therapy 2023, 14:79-84
Published Date: 9 October 2023
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:71-78
Published Date: 7 July 2023
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Brazel D, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:63-69
Published Date: 23 June 2023
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:57-62
Published Date: 22 June 2023
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer
Deck J, Hartley M, Akhter M, Wang D, Bogart JA, Mix MD
Lung Cancer: Targets and Therapy 2023, 14:47-55
Published Date: 19 May 2023
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
Lee ATM, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:41-46
Published Date: 25 April 2023
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel D, Kim J, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:31-39
Published Date: 20 April 2023
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Zhang SS, Lee A, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:27-30
Published Date: 19 April 2023